Cipla Limited has received approval from the National Company Law Tribunal (NCLT), Mumbai Bench for the scheme of amalgamation of Inzpera Healthsciences Limited, its wholly owned subsidiary, with itself. The order, pronounced on August 18, 2026, was passed in CA(CAA)/114/MB/2026 under Sections 230 to 232 of the Companies Act, 2013. The appointed date fixed for the scheme is April 1, 2026. Cipla disclosed the development to stock exchanges on August 19, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Scheme structure and consideration

Inzpera Healthsciences Limited is engaged in the development, manufacturing and marketing of pharmaceutical products, while Cipla is engaged in the manufacturing and marketing of pharmaceutical products. Since Inzpera is a wholly owned subsidiary of Cipla, all equity shares of the transferor company held by Cipla will be cancelled upon amalgamation. No new shares will be issued or allotted to the shareholders of Inzpera, as Cipla itself is the sole shareholder.

Share capital of applicant companies

The authorised, issued, subscribed and paid-up share capital of both applicant companies as stated in the application is set out below.

Inzpera Healthsciences Limited (First Applicant Company):

Cipla Limited (Second Applicant Company):

Meetings dispensed and creditor position

The NCLT dispensed with shareholder and creditor meetings for Inzpera on the basis that the transferor company has seven equity shareholders and one preference shareholder, all of whom provided consent affidavits. As on May 22, 2026, Inzpera had no secured creditors, and its sole unsecured creditor for an amount of Rs. 22,683/- also provided a consent affidavit, dispensing with the need for a creditors meeting.

For Cipla, as on March 31, 2026, there were no secured creditors. As on March 31, 2026, Cipla had 7,567 unsecured creditors aggregating to INR 2,204.85 crores, as certified by an independent chartered accountant. The NCLT held that a formal meeting of Cipla's equity shareholders and creditors was not required, given that Inzpera is a wholly owned subsidiary and the post-merger net worth of Cipla will remain positive. However, the tribunal directed Cipla to issue notice to its shareholders and creditors by courier, registered AD, speed post, or email, allowing them to submit representations to the tribunal. Absence of a response will be treated as no objection to the scheme.

Rationale for amalgamation

The applicant companies cited the following benefits as the rationale for the proposed scheme:

• Consolidation of activities with pooling and more efficient utilisation of resources, greater economies of scale, and reduction in overheads and other expenses
• Greater integration and flexibility to maximise overall shareholder value and improve the competitive position of the combined entity
• Greater efficiency in cash management and access to cash flows of the combined entity for deployment toward organic and inorganic growth opportunities
• Improved organisational capability arising from pooling of human capital with diverse skills and experience
• Cost savings from rationalisation, standardisation and simplification of business processes, and elimination of duplication
• Reduction in multiplicity of entities, thereby reducing compliance costs including statutory filings, regulatory compliances, and labour law related compliances

Regulatory notices and compliance directions

The NCLT directed both applicant companies to serve notice along with a copy of the scheme on several regulatory authorities, including the Central Government through the Regional Director (Western Region-I, Mumbai), the jurisdictional Registrar of Companies, jurisdictional Income Tax Authority, the Principal Chief Commissioner of Income Tax Mumbai, concerned Goods and Service Tax authorities, the concerned Official Liquidator, SEBI, BSE Limited, National Stock Exchange of India, and the National Pharmaceutical Pricing Authority, among others. Notices are to be served through speed post and email under Section 230(5) of the Companies Act, 2013, and Rule 8 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016. Authorities that do not respond within 30 days of receipt of notice will be presumed to have no objection to the proposed scheme. Cipla is also required to file an affidavit of service and compliance report within 10 working days of serving notice to all regulatory authorities.

With respect to the SEBI listing requirements, Cipla noted that since Inzpera is a wholly owned subsidiary, the requirement to obtain a No Objection Certificate from the stock exchanges has been relaxed under Regulation 37(6) of the SEBI Listing Regulations, and the draft scheme was filed with BSE and NSE for disclosure purposes only.

Cipla Limited reported divergent Environmental, Social, and Governance (ESG) ratings for FY26 from two SEBI-registered rating agencies. While SES ESG Research Private Limited (SES) improved the company’s adjusted rating to 69.9 (Grade B), NSE Sustainability Ratings & Analytics Limited (NSE) reduced its score to 67 (Aspiring). The decline in the NSE rating is attributed to a product recall by Cipla USA Inc., a wholly owned subsidiary of the company, in January 2026.

The disclosures were made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The company received the ESG rating reports on August 10, 2026, at 1905 hours IST from SES and 1527 hours IST from NSE.

Rating Comparison

The following table outlines the changes in ESG ratings assigned by SES and NSE for FY26 compared to FY25:

SES maintained the Grade B classification but increased the numerical score from 69.3 in FY25 to 69.9 in FY26. Conversely, NSE retained the 'Aspiring' grade but lowered the numerical score from 69 to 67.

Impact of Operational Events

The divergence in ratings highlights the sensitivity of ESG scores to specific operational incidents. The NSE report explicitly linked the reduction in its rating to the product recall executed by Cipla USA Inc. in January 2026. This event appears to have outweighed other sustainability metrics in the NSE’s assessment framework for the period.

What the Numbers Show

The simultaneous improvement from one agency and decline from another suggests differing weightages assigned to operational compliance versus broader sustainability initiatives. While SES recognized incremental progress in its adjusted scoring model, NSE’s methodology penalized the recent regulatory or quality-related incident in the US market more heavily. Investors should note that ESG ratings are dynamic and can shift based on discrete events such as recalls, independent of long-term strategic sustainability goals.